Medical Physicist to MD | Dedicated to LR-PFS 🎯, QoL, isotoxicity ⚖️, constraints 🙅♀️, & reproducibility 📊 | Creator of @RadOncReview | #RadOncCalc
May 31 • 9 tweets • 2 min read
🧵1/
Big news in unresectable stage III NSCLC.
The InTRist study is the first randomized trial comparing NAC vs. neoadjuvant chemoimmunotherapy (NAC-ICI) prior to definitive chemoradiotherapy (CRT).
Early results are promising. Let’s dig in. 🔍
#LungCancer #RadOnc #ASCO25 2/
📌 Background:
Patients with bulky, unresectable stage III NSCLC remain a major clinical challenge. Prior retrospective data hinted that induction NAC-ICI before CRT might help. InTRist is the first randomized phase II trial to formally test this.
May 18 • 8 tweets • 2 min read
🧵1/
🚨New case report out in Cureus:
Face the Pain: Radiobiological and Clinical Considerations of Re-radiosurgery to the Trigeminal Nerve
👉 A deep dive into a unique case of medically refractory TGN in the setting of a petroclival meningioma.
🔗 doi.org/10.7759/cureus…2/
An 81-year-old woman was treated at an OSH for a trigeminally-symptomatic petroclival meningioma, to 25 Gy in 5 fx.
Despite good tumor control, facial pain persisted, and surgery wasn’t an option.
So… what now?
Dec 26, 2024 • 10 tweets • 4 min read
1/ Treating hepatocellular carcinoma (HCC) with macrovascular invasion (MVI) has always been challenging. New research compares two approaches—surgery and stereotactic body radiotherapy (SBRT)—providing fresh perspectives on how we care for these patients.
Let’s dive in. 🧵 2/ This study used propensity score matching to ensure fair comparisons between the two groups. The primary outcome was overall survival (OS), with secondary outcomes including local control and distant recurrence rates.
Here’s what they found: 🧑⚕️👇
May 4, 2024 • 5 tweets • 4 min read
Fabio Arcidiacono: Five year survival and safety outcomes from the START-NEW-ERA non-randomized phase II trial #ESTRO24 #LCSM #radonc
Jul 26, 2022 • 28 tweets • 26 min read
Is there a role for Local Tx of the Primary Tumor for Patients with Metastatic Cancer?
🚫Many studies demonstrate no benefit.
📌We performed a MetaAnalysis to evaluate the average effect of Local Tx across various tumors.
📌 Many providers think local control of the primary tumor in the setting of M1 dz is akin to “closing the barn door after the horse has bolted”
📌 Ian Tannock wrote a fantastic article on this back in 2000.